These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. One size does not fit all. Facio FM Am J Bioeth; 2006; 6(6):40-2; author reply W10-2. PubMed ID: 17085407 [No Abstract] [Full Text] [Related]
23. Brawl in Beijing. Cyranoski D Nature; 2010 Sep; 467(7315):511. PubMed ID: 20881985 [No Abstract] [Full Text] [Related]
24. Animal welfare is not just another bureaucratic hoop. Bergmeier L Nature; 2007 Jul; 448(7151):251. PubMed ID: 17637639 [No Abstract] [Full Text] [Related]
25. A celebration of Spain's exemplary lab leaders. Abbott A Nature; 2017 Dec; 552(7683):139-140. PubMed ID: 29219971 [No Abstract] [Full Text] [Related]
26. Obligations in offering to disclose genetic research results. Fernandez CV; Weijer C Am J Bioeth; 2006; 6(6):44-6; author reply W10-2. PubMed ID: 17085409 [No Abstract] [Full Text] [Related]
27. Enemy of the good. Nature; 2013 Nov; 503(7477):438. PubMed ID: 24298564 [No Abstract] [Full Text] [Related]
28. Developing excellence: Chinese university reform in three steps. Zhang J Nature; 2014 Oct; 514(7522):295-6. PubMed ID: 25318507 [No Abstract] [Full Text] [Related]
29. Thresholds and boundaries in the disclosure of individual genetic research results. Dressler LG; Juengst ET Am J Bioeth; 2006; 6(6):18-20; author reply W10-2. PubMed ID: 17085396 [No Abstract] [Full Text] [Related]
30. Tiered disclosure options promote the autonomy and well-being of research subjects. Rothstein MA Am J Bioeth; 2006; 6(6):20-1; author reply W10-2. PubMed ID: 17085397 [No Abstract] [Full Text] [Related]
31. Ethical considerations in the communication of unexpected information with clinical implications. Lavieri RR; Garner SA Am J Bioeth; 2006; 6(6):46-8; author reply W10-2. PubMed ID: 17085410 [No Abstract] [Full Text] [Related]
32. The ethical imperative of risk disclosure in research: the answer is always yes. Quinn GP; Haura EB; Murphy D Am J Bioeth; 2014; 14(4):18-9. PubMed ID: 24730484 [No Abstract] [Full Text] [Related]
33. Considering the nature of individual research results. Beskow LM Am J Bioeth; 2006; 6(6):38-40; author reply W10-2. PubMed ID: 17085406 [No Abstract] [Full Text] [Related]
36. The relevance of research study phase to disclosure of off-label drug availability. Baskaran A; Sade RM Am J Bioeth; 2014; 14(4):53-4. PubMed ID: 24730498 [No Abstract] [Full Text] [Related]
37. Disclosure of risks and uncertainties are especially vital in light of regenerative medicine. Niemansburg SL; Habets MG; van Delden JJ; Bredenoord AL Am J Bioeth; 2014; 14(4):14-6. PubMed ID: 24730482 [No Abstract] [Full Text] [Related]
38. Disclosure in scientific meetings: should we take any steps further? Pellicer A; Zupi E Fertil Steril; 2016 Oct; 106(5):1032. PubMed ID: 27692287 [No Abstract] [Full Text] [Related]
39. Quality deficit belies the hype. Huang F Nature; 2018 Dec; 564(7735):S70-S71. PubMed ID: 30542188 [No Abstract] [Full Text] [Related]
40. Sell yourself and your science in a compelling personal statement. Tay A Nature; 2021 May; 593(7857):153-155. PubMed ID: 33893464 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]